“Resuscitation” of marginal liver allografts for transplantation with machine perfusion technology  Jay A. Graham, James V. Guarrera  Journal of Hepatology  Volume 61, Issue 2, Pages 418-431 (August 2014) DOI: 10.1016/j.jhep.2014.04.019 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 1 A representative liver allograft undergoing HMP from the Columbia University Medical Center Liver HMP Clinical Trial (ClinicalTrials.gov: NCT01274520). PV, Portal vein; Ao, Aorta; CHA, Common hepatic artery. Journal of Hepatology 2014 61, 418-431DOI: (10.1016/j.jhep.2014.04.019) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Liver specific cellular and cytokine activation and injuries associated with transplant ischemia/reperfusion injury. Journal of Hepatology 2014 61, 418-431DOI: (10.1016/j.jhep.2014.04.019) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Machine perfusion devices. (A, B) Photograph of Organ Recovery Systems Inc. LifePort® Liver Transporter prototype. (C) ECOPS device (Organ Assist®). (D) The OrganOx® metra™ device. Journal of Hepatology 2014 61, 418-431DOI: (10.1016/j.jhep.2014.04.019) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2014 61, 418-431DOI: (10. 1016/j. jhep. 2014. 04 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions